期刊文献+

胃癌顺铂耐药细胞株的建立和基因表达谱分析 被引量:5

Establishment of DDP-resistant gastric cancer cell line SGC7901 and gene profile analysis
原文传递
导出
摘要 目的建立人胃癌顺铂耐药细胞株,探讨其基因表达谱与顺铂耐药的相关性。方法采用浓度梯度递增法诱导胃癌SGC7901细胞株,建立对顺铂耐药的SGC7901/DDP细胞株。应用Affymetrix基因芯片HG-U133 Plus2.0筛选SGC7901和SGC7901/DDP的耐药相关的差异基因。结果建立可耐受1.0mr,/LJ顷铂浓度的耐药株SGC7901/DDP,耐药指数22.85。应用电镜观察其形态学变化,细胞计数法绘制生长曲线,噻唑蓝(MYr)检测检测药物敏感性,流式细胞术分析细胞周期。利用基因芯片筛选得到在耐药细胞株和敏感株中表达差异大于10倍的基因共107条,其中JNK1和JNK2为与耐药相关的明显上调基因。Western blot证实JNK的磷酸化活性形式P-JNK在耐药株中表达明显升高。SP600125抑制P-JNK表达后耐药蛋白P-gP表达明显减低。结论高通量的基因芯片筛选得到大量有意义的与顺铂耐药相关的差异基因,P-JNK可成为逆转耐药的新的靶点。 Objective To establish cisplatin (DDP)-resistant human gastric cancer cell line and investigate the relationship between differential gene profile and DDP resistance. Methods A DDP-resistant human gastric cancer cell line SGC7901/DDP was established by increasing dose of DDP up to 1.0 mg/L and the resistance index (RI) was 22.85. The multidrug resistance (MDR) phenotype was tested by detecting cell morphology using electron microscopy, drug sensitivity using MTT array, and cell cycle using flow cytometry. Results 107 genes were identified,which were differentially expressed by more than 10 times between SGC7901 and SGC7901/DDP cell lines using Affymetrix gene chip HG-U133 Plus 2.0, among which JNK1 and JNK2 were significantly up-regulated in SGC7901/DDP cell line and the active phosphorylation type of JNK (P-JNK) was verified by Western blot. The expression of MDR protein P-gp was inhibited after the blocking of P-JNK by SP600125. Conclusion Numerous genes relating with DDP- resistance were screened out by through-out gene chip and P-JNK could be the novel target gene for reversing MDR.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2009年第1期31-33,共3页 Chinese Journal of Experimental Surgery
基金 基金项目:上海市自然科学基金资助项目(03ZR14077)
关键词 胃肿瘤 基因芯片 多药耐药 Gastric neoplasm Gene chip Muhidrug resistance
  • 相关文献

参考文献5

二级参考文献1

共引文献9

同被引文献50

  • 1张真发,马建群,张林.有丝分裂激活的蛋白激酶家族基因在非小细胞肺癌中的表达及临床意义[J].中华医学杂志,2005,85(5):339-342. 被引量:4
  • 2胡骁轶,王国民,徐叶青,陈刚,曾蒙苏.高强度聚焦超声治疗兔肾癌细胞株VX2的CT动态观察[J].中华实验外科杂志,2005,22(9):1048-1050. 被引量:6
  • 3Verweij J,Casali PG,Zalcberg J,et al.Progression-free survival in gastrointestinal stromal tumors with high-dose i matinib:randomized trial.Lancet,2004,39:1127-1134.
  • 4Cristina R,Peter B,Tianhua G,et al.Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.Cancer Ther,2005,11:4182-4190.
  • 5Taguchi T,Sonobe H,Toyonaga S,et al.Conventional and molecular cytogenetic characterization of a new human cell line,GIST-T1,established from gastrointestinal stromal tumor.Laboratory Investigation,2002,82:663-665.
  • 6Tuveson DA,Willis NA,Jacks T,et al.STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein:biological and clinical implications.Oncogene,2001,20:5054-5058.
  • 7Mehren M,Blanke CD.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med,2002,347:472-480.
  • 8Prasad SR, Saini S, Sumner JE, et al. Radiologieal measurement of breast cancer metastases to lung and liver: comparison between WHO (bodimensional) and RECIST (unidimensional) guidelines. J Comput Assist Tomogr,2003,27 : 380-384.
  • 9Quaia E. Assessment of tissue perfusion by contrast-enhanced ultra- sound. Eur Radiol,2011,21:604-615.
  • 10Ignee A, Jedrejczyk M, Schuessler G, et al. Quantitative contrast en- hanced ultrasound of the liver for time intensity curves-Reliability and potential sources of errors. Eur J Radiol,2010 ,73 : 153-158.

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部